Fundamentals Data provided by Morningstar.Data provided by Morningstar.
52 Week Range
Avg. Volume (1 month)
as at 24 Feb 3:44pm
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
|Date||Announcement||Price Sensitive?||Time||No. of Pages||File Size|
Mayne Pharma Group Ltd (ASX: MYX) is a specialty pharmaceutical company that applies its drug delivery expertise to commercialise branded and generic pharmaceuticals. The company also provides contract development and manufacturing services to more than 100 clients worldwide.
Mayne Pharma is technology driven with a significant product portfolio and pipeline, and global reach through distribution partners in Australia, North America, Europe and Asia. The company has product development and manufacturing facilities in Salisbury, Australia and Greenville, North Carolina, USA with expertise in formulating complex oral and topical dose forms. The business is supported by more than 900 staff globally with more than 200 scientists employed.
The Salisbury facility is capable of developing products from formulation and clinical trial stages to validation and registration, right through to commercial scale manufacture of packaged goods.
|22 Oct 2021||$0.35||$0.02||6.15%||6,986,130||$0.33||$0.35||$0.32|
|21 Oct 2021||$0.33||$-0.01||-2.99%||7,073,381||$0.34||$0.34||$0.33|
|20 Oct 2021||$0.34||$-0.01||-2.94%||1,844,980||$0.34||$0.35||$0.34|
|19 Oct 2021||$0.34||$-0.01||-2.86%||10,733,750||$0.34||$0.37||$0.34|
|18 Oct 2021||$0.35||$0.04||12.90%||7,923,482||$0.31||$0.35||$0.31|
|15 Oct 2021||$0.31||$0.01||3.33%||918,010||$0.31||$0.31||$0.30|
|14 Oct 2021||$0.30||$-0.01||-3.23%||2,036,419||$0.31||$0.31||$0.30|
|13 Oct 2021||$0.31||$0.01||3.28%||899,894||$0.31||$0.31||$0.30|
|12 Oct 2021||$0.31||$0.01||3.39%||1,259,377||$0.30||$0.31||$0.30|
|11 Oct 2021||$0.30||$-0.01||-3.28%||3,813,153||$0.31||$0.31||$0.30|
|08 Oct 2021||$0.31||$-0.01||-3.17%||4,554,451||$0.32||$0.33||$0.31|
|07 Oct 2021||$0.32||$0.00||0.00%||3,335,651||$0.32||$0.32||$0.31|
|06 Oct 2021||$0.32||$0.01||3.28%||2,499,830||$0.31||$0.32||$0.31|
|05 Oct 2021||$0.31||$-0.01||-3.23%||2,335,617||$0.31||$0.32||$0.31|
|04 Oct 2021||$0.31||$0.02||6.78%||4,287,494||$0.30||$0.32||$0.30|
|01 Oct 2021||$0.30||$0.01||3.51%||956,952||$0.29||$0.30||$0.29|
|30 Sep 2021||$0.29||$0.00||0.00%||1,766,659||$0.29||$0.30||$0.29|
|29 Sep 2021||$0.29||$-0.01||-3.39%||2,947,139||$0.29||$0.30||$0.28|
|28 Sep 2021||$0.30||$-0.01||-3.33%||1,058,942||$0.30||$0.30||$0.29|
|27 Sep 2021||$0.30||$0.01||3.39%||1,845,041||$0.30||$0.31||$0.30|
|24 Sep 2021||$0.30||$0.01||3.51%||1,741,990||$0.29||$0.30||$0.29|
|23 Sep 2021||$0.29||$0.00||0.00%||2,259,304||$0.29||$0.30||$0.29|
|01 Sep 2021||Frank Condella||Buy||412||$136,679|| |
|04 Dec 2020||Scott Richards||Issued||8||$3,072,000|| |
Issue of securities. VWAP
|04 Dec 2020||Scott Richards||Issued||1||$405,177|| |
Issue of securities. 3,681,297 - Performance Rights
|Mr Frank Condella||Non-Executive DirectorNon-Executive Chairman||May 2018|| |
Mr Condella has over 30 years of experience in senior executive roles in the global pharmaceutical industry. His operating experience includes CEO of Juniper Pharmaceuticals, a CDMO and specialty pharmaceutical company, which was subsequently sold to Catalent. Previously he served as CEO of Skyepharma Plc, President of European operations at IVAX (Teva), CEO of Faulding Pharmaceuticals, Vice President of Specialty Care Products at Roche and Vice President and General Manager of the Lederle Standard Products (Pfizer). Mr Condella's previous board experience includes Chairman of Skyepharma Plc until it merged with Vectura, Vice Chairman of Vectura Plc, Independent Director of Prosonix ltd, Independent Director of Fulcrum Pharma plc, and Chairman of the PKD Foundation. He currently also serves as an Independent Director for Fertin Pharma A/S (Denmark) and Palladio Biosciences Inc (US). Mr Condella is a member of Mayne Pharma's Science, Technology and Medical Committee.
|Mr Ian Frank Scholes||Non-Executive DirectorNon-Executive Deputy Chairman||Oct 2007|| |
Mr Scholes has e financial and corporate advisory experience, both in Australia and internationally. Mr Scholes held a number of senior roles within Merrill Lynch Australia, including Managing Director and Vice Chairman of Investment Banking. Previously Mr Scholes held the position of Executive General Manager at National Australia Bank Limited, running the corporate and institutional banking division. Mr Scholes is currently a Partner and CEO of Chord Capital Pty Ltd. Mr Scholes has previously held positions on the Board of St Vincent's Health as Chairman of the St Vincent's Foundation and was a former Director of SDI Limited. Mr Scholes is also Chairman of Mayne Pharma's Risk Committee and a member of the People Committee.
|Ms Nancy Dolan||Non-Executive Director||Sep 2016|| |
Ms Dolan has over 30 years experience in the legal services sector. Ms Dolan is currently Chair of the Professional Conduct Oversight Committee at Chartered Accountants Australia and New Zealand. She was previously General Counsel and a Principal Officer at the University of Sydney, a Partner at PricewaterhouseCoopers in charge for legal affairs in the Asia Pacific region and a Partner at Mallesons Stephen Jacques (now King & Wood Mallesons). Ms Dolan was previously on the Advisory Board of the Sydney Medical School, on the Professional Standards Council for the Salvation Army, a Member of the Advisory Committee for Salvos Legal and on the Salvation Army Advisory Board (Eastern Territory). Ms Dolan is a member of the Risk Committee.
|Mr Scott Anthony Richards||Chief Executive OfficerManaging Director||Feb 2012|| |
Mr Richards has more than 30 years experience in the pharmaceutical industry and has worked in Europe, the US and Asia. Previously, Mr Richards has had spend 10 years in Europe serving leadership roles including President, Europe Middle East and Africa. He also served on the Group Management Board of Actavis for 4 years where he was in charge for the firm's injectable/hospital business operations. Prior to working in Europe, Mr Richards had spend 14 years with FH Faulding and Co., in roles including Faulding Pharmaceuticals Asia Pacific operations together with spending 5 years with Faulding in the US business development and portfolio management operations. Mr Richards experience spans sales and marketing, medical affairs, supply chain, business development, mergers and acquisitions, finance, intellectual property and manufacturing.
|Professor Bruce Gregory Robinson||Non-Executive Director||Aug 2014|| |
Professor Robinson is former Dean of University of Sydney's Sydney Medical School. He has been the head of the Cancer Genetics Unit at the Kolling Institute of Medical Research, Royal North Shore Hospital since 1989. Since 2001, he has been Chairman of Hoc Mai Foundation, a program in medical and health education and exchange with Vietnam. He is a Non-Executive Director of Cochlear Limited, Lorica and QBiotics Group Limited. He is a Board Member of the Woolcock Institute, is Chair of National Health and Medical Research Council and Chair of the Medical Benefits Review Taskforce. Prof Robinson is Chairman of the Science, Technology and Medical Committee.
|Mr Patrick J Blake||Non-Executive Director||Jun 2018|| |
Mr Blake has over 30 years of healthcare industry experience including more than 20 years at McKesson Corporation one of the healthcare services and information technology companies globally, and more than 10 years at Baxter Healthcare Corporation. Recently, he was Executive Vice President of McKesson Corporation and Group President of McKesson Technology Solutions which services the health IT needs of hospitals and health systems, payers, physicians, homecare agencies, retail pharmacies and manufacturers, a position he held from 2009 until 2017. Previously, he was President of McKesson Specialty Health, a business focussed on the US specialty/biotech sector which was McKesson's business for three years during his leadership. He was also President of Customer Operations for McKesson Pharmaceutical (US) from 2000 to 2006, led sales and operations for the wholesale distribution of branded and generic pharmaceuticals and other related products. Mr Blake is a Member of the Risk and People Committee.
|Dr Carolyn Myers||Non-Executive Director||Oct 2021|| |
Dr Myers is an experienced pharmaceutical executive having held senior leadership roles at Allergan, Forest Labs, Mylan (now Viatris) and Pharmacia (now Pfizer). She has 30 years of experience in the pharmaceutical industry and is currently CEO of FendX technologies, a medical technology company formed to develop and commercialise products using a unique pathogenrepelling technology. She is also Principal of BioEnsemble, providing consulting services to small and mid-size pharma, biotech and medical technology companies. Previously, she was Vice President of Global Alliance Management and International Business Development at Allergan, Vice President of Marketing at Forest Laboratories, President of Dey Laboratories and President of Mylan Technologies. Dr Myers is a Steering Committee member of Mid Atlantic Bio Angels, a committee member of Golden Seeds and an independent board member of Hyloris Pharmaceuticals.
|Ms Laura Loftus||Company Secretary||Mar 2020|| |
|Laura Loftus||Company Secretary|| |
|Kate Rintoul||Executive Vice President and General Counsel|| |
|Daniel Moore||Executive Vice President Generic Products Division|| |
|Brant Schofield||Executive Vice President Specialty Brands Division|| |
|Peter Paltoglou||Interim CFO and Chief Development Officer|| |
|Stefan Cross||President International Operations|| |
|John Ross||President Mayne Pharma USA|| |
|Andrew Herdman||Vice President Group Human Resources|| |
|HSBC Custody Nominees (Australia) Limited||320,478,060||19.10%|
|Mr Bruce Mathieson And Related Entities||105,577,583||6.30%|
|J P Morgan Nominees Australia Pty Limited||102,531,522||6.10%|
|Citicorp Nominees Pty Limited||97,467,463||5.80%|
|Solium Nominees (Australia) Pty Ltd <Bare Allocated A/C>||89,184,990||5.30%|
|Solium Nominees (Australia) Pty Ltd <Unallocated A/C>||29,692,951||1.80%|
|BNP Paribas Nominees Pty Ltd <Agency Lending Drp A/C>||26,688,048||1.60%|
|IVL Group Pty Ltd||16,000,000||1.00%|
|BNP Paribas Noms Pty Ltd <Drp>||14,106,094||0.80%|
|Citicorp Nominees Pty Limited <Colonial First State Inv A/C>||14,100,000||0.80%|
|Australian Executor Trustees Limited <Ips Super A/C>||11,327,284||0.70%|
|Mr Roger Corbett And Related Entities||10,440,569||0.60%|
|National Nominees Limited||10,278,401||0.60%|
|Vivnat (Curtin) Pty Ltd||10,000,000||0.60%|
|Y S Chains Pty Ltd||10,000,000||0.60%|
|WAL Assets Pty Ltd <The La Wilson Property A/C>||9,193,503||0.50%|
|R & J Smith Shareholding Pty Ltd <R & J Smith Shareholding A/C>||8,853,084||0.50%|
|Mr Roger Aston & Related Entities||7,140,935||0.40%|
|William P Hodges||6,089,554||0.40%|